


		EMLc	ATC codes: L01EA02
Indication	Chronic myeloid leukaemia, not elsewhere classified	ICD11 code: 2C03.2	
INN	Dasatinib		
Medicine type	Chemical agent		
List type	Complementary (EML) (EMLc)		
Additional notes	Imatinib-resistant chronic myeloid leukaemia		
Formulations	Oral > Solid: 20 mg tablet ; 50 mg tablet ; 70 mg tablet ; 80 mg tablet ; 100 mg tablet (EML) ; 140 mg tablet (EML)		
EML status history	First added in 2017 (TRS 1006) Changed in 2019 (TRS 1021) Changed in 2023 (TRS 1049)		
Sex	All		
Age	Also recommended for children		
Therapeutic alternatives	The recommendation is for this specific medicine		
Patent information	Main patent is active in several jurisdictions. For more information on specific patents and license status for developing countries visit <a href="http://www.MedsPal.org">www.MedsPal.org</a>  Read more <a href="#">about patents.</a> 		
Tags	<span>Cancer</span>		
Wikipedia	<a href="#">Dasatinib</a> 		
DrugBank	<a href="#">Dasatinib</a> 		

### Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended deletion of dasatinib 100 mg and 140 mg tablets from the EMLc.

